Crystallographic analysis revealed that the 17-member polyketide antibiotic lankacidin produced by Streptomyces rochei binds at the peptidyl transferase center of the eubacterial large ribosomal subunit. Biochemical and functional studies verified this finding and showed interference with peptide bond formation. Chemical probing indicated that the macrolide lankamycin, a second antibiotic produced by the same species, binds at a neighboring site, at the ribosome exit tunnel. These two antibiotics can bind to the ribosome simultaneously and display synergy in inhibiting bacterial growth. The binding site of lankacidin and lankamycin partially overlap with the binding site of another pair of synergistic antibiotics, the streptogramins. Thus, at least two pairs of structurally dissimilar compounds have been selected in the course of evolution to act synergistically by targeting neighboring sites in the ribosome. These results underscore the importance of the corresponding ribosomal sites for development of clinically relevant synergistic antibiotics and demonstrate the utility of structural analysis for providing new directions for drug discovery.
The structure of ribosome-lankacidin complex reveals ribosomal sites for synergistic antibiotics Biochemical, genetic and functional evidence indicate that a great variety of antibiotics inhibit protein synthesis by binding to ribosomal functional regions. Crystallographic studies performed over the last decade revealed the exact binding sites of a variety of such drugs (see refs.1 and 2 for review). Many natural antibiotics, as well as their clinically relevant semisynthetic derivatives, bind at the peptidyl transferase center (PTC) in the large ribosomal subunit (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . Most of these compounds inhibit cell growth by interfering with peptide bond formation (15) . The second major antibiotic binding site in the large ribosomal subunit is located at the upper segment of the nascent peptide exit tunnel (NPET), adjacent to the PTC, and is used by macrolides and type B streptogramins (3, 7, (16) (17) (18) (19) (20) (21) . Binding to this site impedes progression of the nascent proteins toward the tunnel exit. Thus, compounds binding to the PTC and NPET inhibit successive steps in protein synthesis: formation of the nascent chains and their export from the ribosome. Simultaneous inhibition of successive steps of a specific biochemical pathway often results in a synergistic action of the inhibitors (22) . Nature has not ignored this opportunity when evolving ribosomal antibiotics. For example, streptogramin antibiotics, produced by several Streptomyces species, are secreted as a combination of two structurally distinct compounds that inhibit cell growth by acting upon the PTC and NPET (23, 24) . Streptogramin A (S A ) compounds are cyclic poly-unsaturated macrolactones that bind in the PTC, whereas type B streptogramins (S B ) compounds are cyclic depsipeptides that bind in the NPET (6, 7, 25) . Each of the individual streptogramin components is a fairly weak antibiotic on its own, but in combination they exhibit strong inhibitory action. The synergistic antibiotic effect of streptogramins is medically relevant-the semisynthetic ]formulation Synercid composed of dalfopristin (the S A derivative) and quinupristin (the S B derivative) is widely used for treatment of complicated Gram-positive infections (26) .
Lankacidin C (LC) and lankamycin (LM) are two inhibitory compounds produced by Streptomyces rochei 7434AN4 (27, 28) . The structures of LC and LM are chemically distinct and rather different from those of streptogramins (Fig. 1) . LC is a macrocyclic compound composed of a 17-membered carbocyclic ring, bridged by a 6-membered lactone. LM is a macrolide whose 14-member lactone ring is decorated with 4-acetyl-L-arcanose and D-chalcose sugars (29, 30) resembling erythromycin (ERY) (Fig. 1) . LC, which is used in veterinary medicine, inhibits growth of Gram-positive bacteria by interfering with protein synthesis but has little effect on eukaryotic cell-free translation (31) (32) (33) (34) . LC and its derivatives also exhibit antitumor activity, although it is unclear whether this phenomenon is related to the drug's effect upon protein synthesis (35) . Lankamycin exhibits a weak antibiotic activity against several Gram-positive bacteria and low toxicity in animal models (36, 37) .
LC competition with chloramphenicol for binding to the ribosome reveals the large ribosomal subunit as a likely target of its action, in accord with its classification as a protein synthesis inhibitor (32, 38) . Though little data is available about activity of LM, the similarity of its structure to that of ERY indicates that it may act as a typical macrolide. Furthermore, similar to ERY and other macrolides, desacetyl-LM was reported to be capable of activating expression of inducible macrolide-resistance genes (37) . Coregulation of production of LC and LM (39, 40) suggests that these drugs have been evolutionary optimized to work together. Nevertheless, although LC and LM are coproduced by the Streptomyces strain, there has been no information about their sites of action, nor any evidence of functional interaction between these two antibiotic compounds.
Here, we investigated the sites of binding and the modes of action of LC and LM by crystallographic and biochemical analyses. We show that these two compounds bind at neighboring sites in the large ribosomal subunit, which partially overlap with the binding sites of two components of streptogramin antibiotics. We present evidence that LC can bind simultaneously with LM, and that the two drugs inhibit bacterial growth synergistically, suggesting that the structures of LC and LM have been optimized in the course of evolution to allow for their simultaneous cooperative action. Based on our structural results we also suggest means for enhancing their synergetic inhibitory effect. This study To whom correspondence should be addressed. E-mail: ada.yonath@weizmann.ac.il or shura@uic.edu.
This article contains supporting information online at www.pnas.org/cgi/content/full/ 0914100107/DCSupplemental. presents the cases in which crystallographic analysis provided functional insights that, in turn, stimulated advanced biochemical and genetic studies, which yielded further clinical implications.
Results
Lankacidin Binding Site. The 3.5 Å resolution (Table S1 ) difference electron density map calculated between the structure amplitudes of the large ribosomal subunits from Deinococcus radiodurans (D50S) in complex with LC (D50S-LC) and of the D50S native structure (41) allowed the unambiguous determination of the location ( Fig. 2A) and conformation of LC in the PTC (Fig. 2B) .
LC binding pocket is composed of nucleotides A2602, C2452, A2503, U2504, G2505, U2585, G2061, and U2506 (E. coli numbering throughout), and the bound LC is involved in an extensive network of hydrophobic interactions with most of these nucleotides. Additionally, LC is positioned within hydrogen bond distance to N1 and N2 of G2061, the 2′ ribose hydroxyls of A2503, and O5′ of G2505 ( Fig. 2B-D) . It partially occupies the location of the amino acid attached to the 3′ end of A site tRNA ( Fig. 3A) and barely reaches the macrolide binding site (Fig. 3C ). The repositioning of the rRNA residues that occurs as a consequence of LC binding creates a unique network of interactions between five reoriented nucleotides: U2506, G2505, G2581, C2610, and G2576. Within this network G2576 stacks upon G2505, C2610 stacks upon G2581, and the exocyclic amine of G2505 is at a hydrogen bonding distance from O2 of C2610. Also, the amino group of G2505 is within a hydrogen bond reach of O4 of U2506, which shifts toward the LC's 1,3 dicarbonyl system. These newly established contacts stabilize the placement of G2505 and U2506 in a conformation that favors binding of LC. Additionally, similar to pleuromutilins that utilize a network of remote interactions, LC binding is influenced by the second-shell nucleotides, specifically G2576, A2062, C2530, U2531, C2507, U2584, G2581, C2610, and A2059. Thus, LC exploits the PTC's inherent flexibility for achieving high binding affinity (9, 10) .
In its binding site, LC macrolactone ring fits in the shallow depression in the wall of the PTC A site, by forming van der Waals interactions with U2504, G2505 and U2506. The importance of these interactions to the drug binding is manifested by structureactivity studies that showed that hydrogenation of the macrocyclic ring alters its ring conformation and reduces the inhibitory activity of LC (43) . The 2-methyl group at the lactone edge of the macrocyclic ring inserts in the opening of the hydrophobic crevice formed by the splayed out bases of A2451 and C2452. This cleft also hosts the aminoacyl moiety of A site-bound aminoacyl-tRNA and is involved in binding of other PTC-targeting antibiotics, including S A antibiotic compounds such as dalfopristin and virginiamycin M (3, 13, 44) . The overlap of the LC and chloramphenicol binding sites (Fig. 3B) provides the structural basis for their competition for binding to the ribosome (32) .
Despite significant size differences (Fig. 1) , the position of LC closely resembles those of dalfopristin (6) and virginiamycin M (4). However, substantial differences were observed in the interactions of these compounds with the ribosome. In the D50S-Synercid complex (6) dalfopristin ring extends significantly farther toward the P site (Fig. 3A) . As LC binds in the PTC center, it causes the flexible base of A2602, which plays a major role in tRNA translocation (42, 45) , to undergo a 45°rotation compared to its placement in native D50S or in Synercid-bound complex. U2585, the second flexible nucleotide that also seems to play a role in A-tRNA translocation, undergoes only a minor alteration in D50S-LC complex, while it is rotated by 180°in D50S-Synercid complex. This rotation seems to occur because of steric hindrance of the dalfopristin large macrocyclic ring and to the occupation of the S B site by quinupristin, the S B component of Synercid. Other important details distinguish binding of LC and dalfopristin. While both drugs are hydrogen-bonded to the G2061 exocyclic amine, an additional H bond links dalfopristin with G2061 2′ hydroxyl (6) . Both LC and Synercid induce a conformational change of C2610. However, in the D50S-LC complex C2610 stacks upon G2581 and is H-bonded to G2505, whereas in the D50S-Synercid complex it is flipped away because of steric hindrance caused by quinupristin. Additionally, while both LC and dalfopristin reorient the U2506 base, the shift of this base toward LC is unique.
Consistent with its binding to the functionally critical PTC, LC inhibited bacterial (E. coli) cell-free transcription-translation system, with a respectable IC 50 of 1.5 AE 0.1 μM (Fig. 4A) .
Furthermore, confirming previous observation (32, 38), we found that the drug readily interfered with the peptide bond formation inhibiting the puromycin reaction catalyzed by either Staphylococcus aureus 70S ribosomes (IC 50 0.32 AE 0.02 μM) or isolated large ribosomal subunits of D. radiodurans (IC 50 10.0 AE 6.0 μM) (Fig. 4B) . This result affirmed LC as an effective PTC inhibitor.
Lankacidin and Lankamycin Can Simultaneously Bind to the Ribosome.
S. rochei secretes two antibiotics, a 17-member ring macrocyclic LC and a 14-member ring macrolide LM. LM is structurally similar to ERY (Fig. 1 ) and thus we assumed that it is likely to bind to the ribosome at the site and orientation similar to ERY, namely at the NPET in immediate proximity to the PTC, the LC binding site. However, the comparison of the position of ERY in D50S (3) with the crystal structure of D50S-LC complex (Fig. 3C) revealed that the desosamine sugar of ERY approaches the macrocyclic ring of LC too close for simultaneous binding of both drugs. In agreement with this notion, competition experiments showed that LC displaced 14 C-ERY from D50S with IC 50 of 355 AE 26 nM (Fig. 4C ). These observations raised the question whether similar to ERY, LM will also compete with LC for ribosome binding. If so, why would an antibioticproducing microorganism synthesize two competing drugs?
Since the lack of radiolabeled LC and LM precluded direct measurement of their binding to the ribosome, we applied an alternative technique to address this puzzle. We first verified that LM binds to the ribosome and inhibits protein synthesis. Indeed, in the E. coli cell-free system, LM inhibited translation (IC 50 of 275 AE 36 μM) (Fig. 4D) , arguing that the antibiotic does bind to the ribosome, albeit with only moderate affinity. RNA probing was then utilized to follow the binding of LC and LM to the ribosome. For the consistency of structural data, we carried out RNA probing experiments using D. radiodurans large ribosomal subunits. Binding of LC and LM was analyzed using chemical modifying reagents 1-cyclohexyl-3-(2-morpholinoethyl) carbodiimide metho-p-toluene sulfonate (CMCT) and dimethyl sulfate (DMS) (46) .
In accord with crystallographic data, association of LC with D50S results in a strong protection of the PTC nucleotide residues U2506 and U2585 from CMCT modification (Fig. 5A) . We also noted that upon LC binding, A2059 became partially protected from DMS, whereas modification of A2058 was increased (Fig. 5B) . This effect correlated with the crystallographic structure of the LC-D50S complex where upon LC binding A2059 is stacked upon A2503, and such stacking may partly expose the surface of A2058, yielding access for DMS. This result indicated that LC-induced restructuring of the D50S nucleotide residues in the PTC can propagate allosterically to the proximal segment of the NPET. Similar to ERY and other 14-member ring macrolides, binding of LM results in protection of U2609 from CMCT modification and of A2058 and A2059 from DMS modification (Fig. 5C and  D) . We then exploited the idiosyncratic protections of 23S rRNA residues against CMCT modification, afforded by LC and LM, to interrogate their simultaneous interaction with the ribosome. At 50 μM, LC shields U2506 and U2585 from alterations. However, the accessibility of these residues to CMCT is not affected by LM or ERY (Fig. 5) . Conversely, LM (at 500 μM) or ERY (at 50 μM) strongly protect U2609, while LC has no effect on this nucleotide. Thus, protection of U2506 and U2585 indicates LC binding, whereas protection of U2609 reveals LM or ERY binding. When LC and LM are present together, all the three residues (U2506, U2585, and U2609) are protected, indicating that LC and LM are simultaneously bound to the ribosome. In contrast, and in agreement with the binding experiments, the LC-mediated protection of U2506 and U2585 is partially relieved upon addition of ERY (Fig. 5D ) and ERY-dependent protection of U2609 is partly reversed when LC is present. Thus, while LC and ERY compete for the binding to the ribosome, LC and LM can bind simultaneously to their respective targets in the PTC and NPET.
LC and LM Act Synergistically Upon Bacterial Cells. Because the binding site of LC and LM partially overlaps with that of S A and S B antibiotics, and because S A and S B act synergistically, we anticipated that despite the difference in their size and chemical properties from streptogramins, LC and LM may also exhibit synergy. To address this issue we performed in vivo and in vitro experiments, using whole cell bacteria as well as a bacterial cell-free system. Synergism was observed by an in vivo assay that utilizes a susceptible strain of Gram-positive S. aureus. We analyzed the minimal inhibitory concentrations (MIC) in a checkerboard fashion and plotted the results as a fraction of MIC (FIC) of individual compounds (Fig. 6) . In this assay, antibiotics are considered synergistic if the curve has a concave shape, whereas a linear plot reflects additive action of the drugs, and a convex graph shows antagonistic interaction (47) . The experimental MIC plot (solid line in Fig. 6 ) had a well-pronounced concave character revealing synergy in action of LC and LM. These findings were further verified in an E. coli cell-free transcription-translation system. Thus, similar to streptogramins, the two antibacterial compounds produced by S. rochei bind simultaneously to the neighboring sites in the ribosome and synergistically inhibit sensitive bacteria.
Discussion
The crystallographic and biochemical data presented here firmly established the PTC as the site of LC action. The inhibitory effect of the antibiotic upon peptide bond formation is likely achieved by preventing the binding or the proper placement of aminoacyl moiety of aminoacyl-tRNA in the A site (Fig. 3A) . As LC trespasses the P site, it may also affect the exact positioning of the peptidyl tRNA C terminus. Although LC is chemically distinct and is less bulky than most S A -type drugs, its binding site partially overlaps with that of S A compounds (4, 6). Furthermore, both, LC and S A drugs and U2506 that is involved in PTC functions (42, (48) (49) (50) .
As can be concluded from the similarity of chemical structures of LM and ERY and from the overlap of the set of nucleotides protected by these two compounds, LM binds to the NPET macrolide binding site in a fashion similar, albeit not identical, to the other macrolides (Fig. 5) . The same NPET region accommodates the B components of streptogramin antibiotics, but owing to differences in chemical nature (Fig. 1) , the S B compounds and macrolides exploit a different set of interactions (3, 4, 6, 7) .
Because the LC and S A binding sites in the PTC (Fig. 3C ) are adjacent to the macrolides and S B binding sites, it is conceivable that compounds acting upon these two sites can either compete or cooperate in binding to the ribosome. Streptogramins are known for their synergistic action (24, 51) . Such cooperativity makes evolutionary sense: The same microorganism produces both S A and S B components, and their mutually enhanced action should be highly beneficial for the antibiotic producer. This notion initially did not seem to hold true for the macrocyclic LC and a macrolide LM. Our experiments showed that LC and ERY do not cooperate, but rather compete for binding to the D. radiodurans ribosome. Hindrance may result from a direct clash between ERY desosamine sugar and the LC macrocyclic ring (Fig. 3C) or by allosteric modulation of the binding site of one compound by binding of its counterpart. The altered DMS reactivity of A2058 and A2059, the nucleotides located in the heart of the macrolide binding site (Fig. 5A) , upon the LC binding might be a reflection of such allostery. However, the competition between LC and ERY is not so surprising: These drugs are produced by different microorganisms and were not "designed" to work together. In contrast, LM is coproduced with LC. Both drugs appear to be coregulated, and thus similar to the streptogramins case, seem to be intended to work together (39, 40) . In agreement with this hypothesis, our results show their simultaneous binding to the ribosome. The small structural differences between ERY and LM ( Fig. 1 ) are likely to cause the variation in their binding properties. One of the important distinctions between LM and ERY is the nature of the C5-linked sugar residue (D-desosamine in ERY vs. D-chalcose in LM). Even small modifications of desosamine in ERY can dramatically alter the antibiotic's activity (52, 53) . Replacement of 3′ dimethyl amine of ERY with a methoxy group in LM may facilitate accommodation of the C5-sugar residue in a narrow space left between the A2058/A2059 ridge and the bound LC molecule (see Fig. 3C ). Similarly, minute modifications in the structure of the antibiotics or in their binding sites may have significant effects on their binding and properties (20, 37, 54, 55) . LM on its own is a less potent protein synthesis inhibitor than ERY. However, LM reduced activity is compensated by its ability to act synergistically with LC. Thus, it appears that the LM synthetic pathway has been evolutionary optimized to generate a 14-member ring macrolide capable of simultaneous binding and synergistic action with LC. It is hardly a coincidence that two different combinations of synergistic protein synthesis inhibitors, the S A and S B components of streptogramins or LC and LM, utilize the same two adjacent sites in the large ribosomal subunit. These sites might be best suited within the ribosome for accommodating pairs of compounds that would be able to tightly bind and inhibit protein synthesis in a synergistic fashion. Previously, significant resources went into development of streptogramins into a clinical drug. This effort resulted in a useful and successful streptogramin antibiotic, Synercid. Yet, to the best of our knowledge, no focused attempt was dedicated to optimizing the combination of LC/LM or, for that matter, LC with any other macrolide. Our studies demonstrate the validity of LC/LM synergism and provide a structural basis for chemical modifications of either of the two components, which could lead to the improvement of the inhibitory action of the LC/LM pair and its clinical relevance. Notably, the S A compounds (for example quinupristin or virginiamycin S) are significantly larger than LC (Figs. 1 and 3A) and therefore have more chemical entities facilitating their binding to the ribosome pocket and forming a stable network of interactions. It is likely, therefore, that decorating LC with additional groups capable of forming new interaction with rRNA in its binding site may increase its affinity. Modulating the properties of the LM sugar residues may further add to the potency of the LC/LM pair.
Conclusions
We showed that two antibiotics, LC and LM, produced by S. rochei are protein synthesis inhibitors that act upon neighboring sites in the large ribosomal subunit and that their simultaneous action synergistically inhibits growth of sensitive bacteria. Our structural and biochemical data imply that optimization of this drug pair leading to high affinity concurrent binding to the ribosome may be reached by minor chemical alterations. Furthermore, our results suggest that certain combinations of PTC inhibitors with the NPET-bound compounds in their natural or chemically modified versions might exhibit synergy. Exploring such drug combinations by co-optimizing their structure or by linking them together into a single molecule may pave the way for the development of advanced antibiotics targeting the ribosome.
Materials and Methods
Crystals of D50S, grown as in ref. 41 , were soaked in a solution containing lankacidin. Crystallographic data were collected with highly collimated synchrotron x-ray beam and processed with HKL2000 (56) and CCP4 (57) using the available crystal structure of lankacidin C (29) . After map tracing and refinement by COOT (58) and CNS (59, 60) ribosome-antibiotic interactions were identified by LigPlot (61) and LPC (62) , and images were generated by PyMol (63) . Coordinates were deposited in the protein data bank (PDB) with accession code 3JQ4.
Antibiotic binding and inhibition of cell-free translation were determined as described in ref. 64 . Inhibition of the peptidyl transferase reaction by LC was performed and analyzed as described in refs. 65 and 66. The data were analyzed using Prism 4 (GraphPad Software). RNA probing was carried out as described in ref. 16 and 46 using D50S. Additional details can be found in SI Text.
